MetaStat Stock

MetaStat PP&E per Employee

The PP&E per Employee of MetaStat (MTST) as of Sep 5, 2026 is 59,016.67 USD. In the previous year, PP&E per Employee was 69,100.00 USD — a change of -14.59% (lower).

PP&E per Employee

59,016.67USD

YoY

-14.59%

Last updated:

PP&E per Employee of MetaStat is 2026 59,016.67 USD. PP&E per Employee of MetaStat was 2025 69,100.00 USD. It decreases by -14.59% lower compared to the previous year.

The MetaStat PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2014
34,033.33 USD
Jan 1, 2015
87,766.67 USD
Jan 1, 2016
82,850.00 USD
Jan 1, 2017
69,100.00 USD
Jan 1, 2018
59,016.67 USD
The MetaStat PP&E per Employee history
YEARPP&E per EmployeeYoY
59,016.67USD-14.59%
69,100.00USD-16.60%
82,850.00USD-5.60%
87,766.67USD+157.88%
34,033.33USD
Access this data via the Eulerpool API

MetaStat Stock analysis

What does MetaStat do? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaStat stock

PP&E per Employee of MetaStat is 59,016.67 USD in 2026.

PP&E per Employee of MetaStat changed from 69,100.00 USD to 59,016.67 USD, representing a -14.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee MetaStat since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's MetaStat historically and in real time.

Access this data via the Eulerpool API

Workforce — MetaStat

All Key Metrics — MetaStat